JP2019531286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531286A5 JP2019531286A5 JP2019513922A JP2019513922A JP2019531286A5 JP 2019531286 A5 JP2019531286 A5 JP 2019531286A5 JP 2019513922 A JP2019513922 A JP 2019513922A JP 2019513922 A JP2019513922 A JP 2019513922A JP 2019531286 A5 JP2019531286 A5 JP 2019531286A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- composition according
- subject
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 42
- 201000006417 multiple sclerosis Diseases 0.000 claims description 31
- 230000004064 dysfunction Effects 0.000 claims description 13
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 9
- 230000001054 cortical effect Effects 0.000 claims description 8
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims description 7
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- -1 drugs Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394046P | 2016-09-13 | 2016-09-13 | |
| US62/394,046 | 2016-09-13 | ||
| US201662436356P | 2016-12-19 | 2016-12-19 | |
| US62/436,356 | 2016-12-19 | ||
| US201762460868P | 2017-02-19 | 2017-02-19 | |
| US62/460,868 | 2017-02-19 | ||
| US201762491071P | 2017-04-27 | 2017-04-27 | |
| US62/491,071 | 2017-04-27 | ||
| PCT/US2017/051414 WO2018053040A1 (en) | 2016-09-13 | 2017-09-13 | Treatment of multiple sclerosis with chs-131 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531286A JP2019531286A (ja) | 2019-10-31 |
| JP2019531286A5 true JP2019531286A5 (enExample) | 2020-10-22 |
Family
ID=61619253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513922A Pending JP2019531286A (ja) | 2016-09-13 | 2017-09-13 | Ｃｈｓ−１３１による多発性硬化症の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190224186A1 (enExample) |
| EP (1) | EP3512512A4 (enExample) |
| JP (1) | JP2019531286A (enExample) |
| KR (1) | KR20190064583A (enExample) |
| CN (1) | CN110461318A (enExample) |
| AU (1) | AU2017326261A1 (enExample) |
| BR (1) | BR112019004791A2 (enExample) |
| CA (1) | CA3036694A1 (enExample) |
| IL (1) | IL265259A (enExample) |
| MX (1) | MX2019002901A (enExample) |
| SG (1) | SG10202102198RA (enExample) |
| WO (1) | WO2018053040A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| EA201992364A1 (ru) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EA201590726A1 (ru) * | 2012-10-12 | 2015-10-30 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для уменьшения таламического поражения при рассеянном склерозе |
| BR112015018048A2 (pt) * | 2013-01-30 | 2020-01-28 | Intekrin Therapeutics Inc | agonistas de ppary para tratamento de esclerose múltipla |
-
2017
- 2017-09-13 SG SG10202102198RA patent/SG10202102198RA/en unknown
- 2017-09-13 JP JP2019513922A patent/JP2019531286A/ja active Pending
- 2017-09-13 BR BR112019004791A patent/BR112019004791A2/pt not_active Application Discontinuation
- 2017-09-13 MX MX2019002901A patent/MX2019002901A/es unknown
- 2017-09-13 US US16/333,171 patent/US20190224186A1/en not_active Abandoned
- 2017-09-13 CA CA3036694A patent/CA3036694A1/en not_active Abandoned
- 2017-09-13 AU AU2017326261A patent/AU2017326261A1/en not_active Abandoned
- 2017-09-13 KR KR1020197009963A patent/KR20190064583A/ko not_active Ceased
- 2017-09-13 WO PCT/US2017/051414 patent/WO2018053040A1/en not_active Ceased
- 2017-09-13 CN CN201780069826.5A patent/CN110461318A/zh not_active Withdrawn
- 2017-09-13 EP EP17851479.0A patent/EP3512512A4/en not_active Withdrawn
-
2019
- 2019-03-10 IL IL265259A patent/IL265259A/en unknown